Current Report Filing (8-k)
July 05 2017 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 5, 2017
Array BioPharma Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-16633
|
84-1460811
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S.
Employer Identification No.)
|
3200 Walnut Street, Boulder, Colorado
80301
(Address of principal executive
offices, including Zip Code)
(303) 381-6600
(Registrant’s telephone number,
including area code)
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act.
¨
In this report, “Array BioPharma,” “Array,”
“we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.
On July 5, 2017, Array issued a press release announcing the
submission of New Drug Applications to the Food and Drug Administration for binimetinib and encorafenib in patients with advanced
BRAF-mutant melanoma.
A copy of the press release is attached to this Form 8-K as
Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
Exhibit
No.
|
|
Description
|
99.1
|
|
Press release announcing the submission of New Drug Applications
to the Food and Drug Administration for binimetinib and encorafenib in patients with advanced BRAF-mutant melanoma
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 5, 2017
|
Array BioPharma Inc.
|
|
|
|
By:
|
/s/ Jason Haddock
|
|
|
Jason Haddock
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
99.1
|
|
Press release announcing the submission of New Drug Applications
to the Food and Drug Administration for binimetinib and encorafenib in patients with advanced BRAF-mutant melanoma
|
Array Technologies (NASDAQ:ARRY)
Historical Stock Chart
From Apr 2024 to May 2024
Array Technologies (NASDAQ:ARRY)
Historical Stock Chart
From May 2023 to May 2024